Openbookopenbook
Equity
4D Molecular Therapeutics Inc(FDMT)
USD --+0.00%
Reward36Moderate
Risk59Medium-High
📊75%Data
Revenue growing 2900% YoY
FDMT
+0.0 · +0.00%
USD · NASDAQ
4D Molecular Therapeutics Inc | Healthcare
Value Trap
Market Cap:575.35M
ℹ️
Reward Rating
36
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
59
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on FDMT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $33.11.

What is 4D Molecular Therapeutics Inc?

, a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

FDMT · Verdict

Limited reward · elevated risk

FDMT's standout is balance sheet; volatility and cash flow weigh on the picture.

Based on 88% data coverage

FDMT · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet93/100

    Current ratio 14.92

Watchouts 4

  • Volatility5/100

    Weak vs peers

  • Cash flow6/100

    -373976% free-cash-flow margin

  • Growth21/100

    Rev -87.3% CAGR · earnings +33.1%

  • Profitability32/100

    -434778% net margin · -45% ROE

Model-based scoring. For information only — not financial advice.

What is 4D Molecular Therapeutics Inc?

, a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 575.35M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap575.35M
P/E RatioN/A
Dividend YieldN/A
52 Week High12.34
52 Week Low2.235
Last AnnualDecember
IPO Date12/11/2020
IncorporatedUSA
Shares Outstanding51M
No. of Employees227
IndustryBiotechnology
ExchangeNASDAQ
Beta3.009
CurrencyUSD
Websitewww.4dmoleculartherapeutics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.